Download PDF
J Pediatr Infect Dis 2019; 14(03): 103-107
DOI: 10.1055/s-0038-1675582
Original Article
Georg Thieme Verlag KG Stuttgart · New York

Tigecycline Use in Neonates: 5-Year Experience of a Tertiary Center

Mehmet Sah İpek
1   Division of Neonatology, Department of Pediatrics, Memorial Dicle Hospital, Diyarbakir, Turkey
,
Mehmet Emin Gunel
2   Department of Pediatrics, Memorial Dicle Hospital, Diyarbakir, Turkey
,
Erdal Ozbek
3   Department of Microbiology, Diyarbakir Maternity and Children Hospital, Diyarbakir, Turkey
› Author Affiliations
Further Information

Publication History

25 March 2018

26 September 2018

Publication Date:
09 November 2018 (online)

Also available at
    Permissions and Reprints

Abstract

The off-label use of tigecycline to treat serious infections has been reported in pediatric patients. We report four newborn infants diagnosed with sepsis caused by extensively drug-resistant Klebsiella pneumoniae and successfully treated with tigecycline. If no alternative drugs are available, tigecycline may be considered as an option for nosocomial infections even in newborn infants. However, further reports are needed to establish its efficacy and safety.

Keywords

tigecycline - neonate - infection - thrombocytopenia
 

  • References

  • 1 Mastrolia MV, Galli L, De Martino M, Chiappini E. Use of tigecycline in pediatric clinical practice. Expert Rev Anti Infect Ther 2017; 15 (06) 605-612
    CrossrefPubMedGoogle Scholar
  • 2 Tygacil: FDA full prescribing information. June 1, 2016. Available at: http://www.fda.gov . Accessed December 15, 2017
    PubMed
  • 3 Iosifidis E, Violaki A, Michalopoulou E. , et al. Use of tigecycline in pediatric patients with infections predominantly due to extensively drug-resistant gram-negative bacteria. J Pediatric Infect Dis Soc 2017; 6 (02) 123-128
    CrossrefPubMedGoogle Scholar
  • 4 Hurtado IC, Trujillo M, Restrepo A, Garcés C, Tamayo C, Mesa JG. Experience with tigecycline compassionate use in pediatric patients infected with carbapenem resistant Klebsiella pneumoniae [Article in Spanish]. Rev Chilena Infectol 2012; 29 (03) 317-321
    CrossrefPubMedGoogle Scholar
  • 5 Zhu ZY, Yang JF, Ni YH, Ye WF, Wang J, Wu ML. Retrospective analysis of tigecycline shows that it may be an option for children with severe infections. Acta Paediatr 2016; 105 (10) e480-e484
    CrossrefPubMedGoogle Scholar
  • 6 Prot-Labarthe S, Youdaren R, Benkerrou M, Basmaci R, Lorrot M. Pediatric acute pancreatitis related to tigecycline. Pediatr Infect Dis J 2010; 29 (09) 890-891
    PubMedGoogle Scholar
  • 7 Emiroglu M, Alkan G, Turk Dagi H. Tigecycline therapy in an infant for ventriculoperitoneal shunt meningitis. Pediatrics 2017; 139 (01) 139
    Google Scholar
  • 8 Purdy J, Jouve S, Yan JL. , et al. Pharmacokinetics and safety profile of tigecycline in children aged 8 to 11 years with selected serious infections: a multicenter, open-label, ascending-dose study. Clin Ther 2012; 34 (02) 496-507.e1
    CrossrefPubMedGoogle Scholar
  • 9 Magiorakos AP, Srinivasan A, Carey RB. , et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 2012; 18 (03) 268-281
    CrossrefPubMedGoogle Scholar
  • 10 Zeng J, Zhang L, Gao M. , et al. Tigecycline treatment in an infant with extensively drug-resistant Acinetobacter baumannii bacteremia. Int J Infect Dis 2017; 61: 23-26
    CrossrefPubMedGoogle Scholar
  • 11 Ramirez J, Dartois N, Gandjini H, Yan JL, Korth-Bradley J, McGovern PC. Randomized phase 2 trial to evaluate the clinical efficacy of two high-dosage tigecycline regimens versus imipenem-cilastatin for treatment of hospital-acquired pneumonia. Antimicrob Agents Chemother 2013; 57 (04) 1756-1762
    CrossrefPubMedGoogle Scholar
  • 12 Ni W, Han Y, Liu J. , et al. Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: a systematic review and meta-analysis. Medicine (Baltimore) 2016; 95 (11) e3126
    PubMedGoogle Scholar
  • 13 Daikos GL, Tsaousi S, Tzouvelekis LS. , et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58 (04) 2322-2328
    CrossrefPubMedGoogle Scholar
  • 14 Gonzalez-Padilla M, Torre-Cisneros J, Rivera-Espinar F. , et al. Gentamicin therapy for sepsis due to carbapenem-resistant and colistin-resistant Klebsiella pneumoniae. J Antimicrob Chemother 2015; 70 (03) 905-913
    CrossrefPubMedGoogle Scholar
  • 15 Shabaan AE, Nour I, Elsayed Eldegla H, Nasef N, Shouman B, Abdel-Hady H. Conventional versus prolonged infusion of meropenem in neonates with gram-negative late-onset sepsis: a randomized controlled trial. Pediatr Infect Dis J 2017; 36 (04) 358-363
    CrossrefPubMedGoogle Scholar
  • 16 Eckmann C, Heizmann W, Bodmann KF, von Eiff C, Petrik C, Loeschmann PA. Tigecycline in the treatment of patients with necrotizing skin and soft tissue infections due to multiresistant bacteria. Surg Infect (Larchmt) 2015; 16 (05) 618-625
    CrossrefPubMedGoogle Scholar
  • 17 Kenney B, Stack G. Drug-induced thrombocytopenia. Arch Pathol Lab Med 2009; 133 (02) 309-314
    CrossrefPubMedGoogle Scholar
  • 18 İpek MS, Aktar F, Okur N, Celik M, Ozbek E. Colistin use in critically ill neonates: a case-control study. Pediatr Neonatol 2017; 58 (06) 490-496
    CrossrefPubMedGoogle Scholar